Seminars in Hematology
Volume 44, Issue 4 , Pages 227-233 , October 2007

High-Dose Treatment With Autologous Stem Cell Transplantation in Multiple Myeloma: Past, Present, and Future

  • Bo Björkstrand

      Affiliations

    • Corresponding Author InformationAddress correspondence to Bo Björkstrand, MD, PhD, Hematology Center, M54, Karolinska University Hospital Huddinge, SE-14186 Stockholm, Sweden.
    • ,
  • Gösta Gahrton

References 

  1. McElwain TJ, Powles RL. High dose intravenous melphalan for plasma cell leukaemia and myeloma. Lancet. 1983;2:822–824
  2. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986;67:1298–1301
  3. Björkstrand B, Hagman A, Ljungman P, Reiffers J, Goldschmidt H, Mandelli F, et al. Autologous stem cell transplantation in multiple myeloma—The 2000 EBMT registry update. Bone Marrow Transplant. 2001;27(suppl 1):S40
  4. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000;95:4008–4010
  5. Attal M, Harousseau J-L, Facon T, Guilhot F, Doyen C, Fuzibet J-G, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495–2502
  6. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood. 2001;97:1566–1571
  7. Fassas AB, Spencer T, Sawyer J, Zangari M, Lee CK, Anaissie E, et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol. 2002;118:1041–1047
  8. Shaughnessy J, Jacobson J, Sawyer J, McCoy J, Fassas A, Zhan F, et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: Interpretation in the context of global gene expression. Blood. 2003;101:3849–3856
  9. Shaughnessy J, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: Early results of total therapy II. Br J Haematol. 2003;120:44–52
  10. Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107:3474–3480
  11. Cavo M, Terragna C, Renzulli M, Zamagni E, Tosi P, Testoni N, et al. Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: Low complete remission rate and short duration of remission. J Clin Oncol. 2006;24:4–5
  12. Björkstrand B, Goldstone AH, Ljungman P, Brandt L, Brunet S, Carlson K, et al. Prognostic factors in autologous stem cell transplantation for multiple myeloma: An EBMT registry study. Leuk Lymphoma. 1994;15:265–272
  13. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91–97
  14. Lahuerta JJ, Martinez-Lopez J, Serna JD, Blade J, Grande C, Alegre A, et al. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol. 2000;109:438–446
  15. Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant. 2001;27:1037–1043
  16. O’Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V, et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: A single-centre experience in 211 patients. Bone Marrow Transplant. 2006;37:731–737
  17. Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, et al. Total therapy 2 without thalidomide in comparison with total therapy 1: Role of intensified induction and posttransplantation consolidation therapies. Blood. 2006;107:2633–2638
  18. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol. 2001;114:822–829
  19. Sirohi B, Powles R, Kulkarni S, Rudin C, Saso R, Rigg A, et al. Glomerular filtration rate prior to high-dose melphalan 200 mg/m2 as a surrogate marker of outcome in patients with myeloma. Br J Cancer. 2001;85:325–332
  20. Carlson K. Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival. Bone Marrow Transplant. 2005;35:985–990
  21. Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J, et al. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: A British Society of Blood and Marrow Transplantation study. Br J Haematol. 2006;134:385–390
  22. Harousseau JL, Attal M. High-dose therapy in multiple myeloma. Hematol J. 2003;4:163–170
  23. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–1883
  24. Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: Results of a randomized controlled trial. Blood. 2004;104:3052–3057
  25. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89:789–793
  26. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Lanng Nielsen J, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study. Blood. 2000;95:7–11
  27. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005;23:9227–9233
  28. Blade J, Rosinol L, Sureda A, Ribera JM, Diaz-Mediavilla J, Garcia-Larana J, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood. 2005;106:3755–3759
  29. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006;24:929–936
  30. Harousseau JL, Milpied N, Garand R, Bourhis JH. High dose melphalan and autologous bone marrow transplantation in high risk myeloma. Br J Haematol. 1987;67:493
  31. Vesole DH, Barlogie B, Jagannath S, Cheson B, Tricot G, Alexanian R, et al. High-dose therapy for refractory multiple myeloma: Improved prognosis with better supportive care and double transplants. Blood. 1994;84:950–956
  32. Björkstrand B, Ljungman P, Bird JM, Samson D, Gahrton G. Double high-dose chemo-radiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma. Bone Marrow Transplant. 1995;15:367–371
  33. Fermand J-P, Alberti C, Marolleau J-P. Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34-enriched ABSC: Results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM). Hematol J. 2003;4(suppl 1):S59
  34. Cavo M, Cellini C, Zamagni E, Cangini D, Tacchetti P, Testoni N, et al. Update on high-dose therapy—Italian studies. Haematologica. 2005;90(suppl 1):39–40
  35. Goldschmidt H. Single vs. double high-dose therapy in multiple myeloma: Second analysis of the GMMG-HD2 trial. Haematologica. 2005;90(suppl 1):38
  36. Sonneveld P, van der Holt B, Segeren CM, Vellenga E, Croockewit AJ, Verhoef GEG, et al. Intensive versus double intensive therapy in untreated multiple myeloma: Update analysis of the randomized phase III HOVON 24 study. Haematologica. 2005;90(suppl 1):37–38
  37. Morris C, Iacobelli S, Brand R, Bjorkstrand B, Drake M, Niederwieser D, et al. Benefit and timing of second transplantations in multiple myeloma: Clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study. J Clin Oncol. 2004;22:1674–1681
  38. Turesson I, Zettervall O, Cuzik J, Waldenström JG, Velez R. Comparison of trends in the incidence of multiple myeloma in Malmö, Sweden, and other countries. N Engl J Med. 1984;310:421–424
  39. Jantunen E, Kuittinen T, Penttila K, Lehtonen P, Mahlamaki E, Nousiainen T. High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (> or = 65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant. 2006;37:917–922
  40. Lenhoff S, Hjorth M, Westin J, Brinch L, Backstrom B, Carlson K, et al. Impact of age on survival after intensive therapy for multiple myeloma: A population-based study by the Nordic Myeloma Study Group. Br J Haematol. 2006;133:389–396
  41. Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol. 2001;114:600–607
  42. Alexanian R, Haut A, Khan A, Lane M, McKelvey EM, Migliore PJ, et al. Treatment for multiple myeloma: Combination chemotherapy with different melphalan dose regimens. JAMA. 1969;208:1680–1685
  43. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Renaud M, et al. Major superiority of melphalan-prednison (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. Blood. 2005;106:230a;(abstr)
  44. Bird JM, Bloxham D, Samson D, Marcus RE, Russell NH, Kelsey SM, et al. Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients. Br J Haematol. 1994;88:110–116
  45. Mariette X, Fermand J-P, Brouet J-C. Myeloma cell contamination of peripheral blood stem cell grafts in patients with multiple myeloma treated by high-dose therapy. Bone Marrow Transplant. 1994;14:47-45 40
  46. Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: Results of a multicenter randomized controlled trial. J Clin Oncol. 2001;19:3771–3779
  47. Bourhis JH, Bouko Y, Koscielny S, Bakkus M, Greinix H, Derigs G, et al: Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: Long term follow-up of an EBMT phase III randomized study. Haematologica (in press)
  48. Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood. 2002;99:731–735
  49. Dimopoulos MA, Alexanian R, Przepiorka D, Hester J, Andersson B, Giralt S, et al. Thiotepa, busulfan, and cyclophosphamide: A new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood. 1993;82:2324–2328
  50. Schiller G, Nimer S, Vescio R, Lieb G, Lee M, Gajewski J, et al. Phase I-II study of busulfan and cyclophosphamide conditioning for transplantation in advanced multiple myeloma. Bone Marrow Transplant. 1994;14:131–136
  51. Moreau P, Milpied N, Mahe B, Juge-Morineau N, Rapp MJ, Bataille R, et al. Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant. 1999;23:1003–1006
  52. Giralt S, Bensinger W, Goodman M, Podoloff D, Eary J, Wendt R, et al. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: Results of two phase 1/2 trials. Blood. 2003;102:2684–2691
  53. Moreau P, Hullin C, Garban F, Yakoub-Agha I, Benboubker L, Attal M, et al. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: Final results of the prospective and randomized IFM 99-04 protocol. Blood. 2006;107:397–403
  54. Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C, et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: Long-term follow-up results. Br J Haematol. 1998;102:495–502
  55. Björkstrand B, Svensson H, Goldschmidt H, Ljungman P, Apperley J, Mandelli F, et al. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: A retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2001;27:511–515
  56. Gojo I, Meisenberg B, Guo C, Fassas A, Murthy A, Fenton R, et al. Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma. Bone Marrow Transplant. 2006;37:65–72
  57. Chen CI, Nanji S, Prabhu A, Beheshti R, Yi QL, Sutton D, et al. Sequential, cycling maintenance therapy for post transplant multiple myeloma. Bone Marrow Transplant. 2006;37:89–94
  58. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108:3289–3294
  59. Björkstrand B, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma—A retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood. 1996;88:4711–4718
  60. Gahrton G, Svensson H, Cavo M, Apperley J, Bacigalupo A, Björkstrand B, et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983-1993 and 1994-1998 at EBMT centers. Br J Haematol. 2001;113:209–216
  61. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356:1110–1120
  62. Tricot G, Spencer T, Sawyer J, Spoon D, Desikan R, Fassas A, et al. Predicting long term (>5 yr) event-free survival in multiple myeloma patients following planned tandem autotransplants. Blood. 2002;116:211–217
  63. Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005;129:755–762
  64. Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Results of an IFM phase II study. Haematologica. 2006;91:1498–1505

 Supported by the Swedish Cancer Society and the Stockholm Cancer Society.

PII: S0037-1963(07)00126-6

doi: 10.1053/j.seminhematol.2007.08.010

Seminars in Hematology
Volume 44, Issue 4 , Pages 227-233 , October 2007

Article Tools

* Image Usage & Resolution